Information Provided By: 
Fly News Breaks for March 28, 2017
SNY, REGN
Mar 28, 2017 | 07:35 EDT
Leerink analyst Geoffrey Porges says Regeneron (REGN) and Sanofi (SNY) should receive notification from the FDA that Dupixent has been approved for atopic dermatitis this week. The analyst expects Dupixent to face some barriers, particularly in adding a regular biweekly injectable, and believes the product may be priced at the low end of the range for injectable treatments for psoriasis. He reiterates an Outperform rating and $448 price target on Regeneron's shares.
News For REGN;SNY From the Last 2 Days
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
